PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26223F0045Eliglustat cerdelga 84mg for VA SD — Genzyme Corp

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Oct 26, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Genzyme Corp

Recipient

Oct 26, 2023

PoP end

$246K

Obligated

$261K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Genzyme Corp — $90

Contract facts

Federal

Contract number36C26223F0045

Also listed as36C262-23-F-0045

Also listed as36F79719D0153-36C26223F0045

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentGenzyme Corp

CAGE1HBD8

UEIX2XMAQLR9DA8

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0153

Place of performancePITTSBURGH PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 27, 2022

PoP end (current)Oct 26, 2023

Obligated$246K

Current value$261K

Potential value$261K

ELIGLUSTAT CERDELGA 84MG FOR VA SD is a federal award for 262-Network Contract Office 22 (36C262) held by Genzyme Corp. Estimated value $261K ($246K obligated). Current period of performance ends Oct 26, 2023. Last award drew 1 bidder. Place of performance: PITTSBURGH PA.

Recompete timing

Public

● Past PoP end (1030 days ago)

Current PoP ended Oct 26, 2023 (1030 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26223F0045?

36C26223F0045 (Eliglustat cerdelga 84mg for VA SD) is a 262-Network Contract Office 22 (36C262) award with a potential value of $261K, currently held by Genzyme Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-23-F-0045?

36C262-23-F-0045 is the dashed form of PIID 36C26223F0045 (Eliglustat cerdelga 84mg for VA SD), held by Genzyme Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26223F0045?

262-Network Contract Office 22 (36C262) awarded 36C26223F0045 to Genzyme Corp (potential $261K).

Who is the incumbent on 36C26223F0045?

Genzyme Corp is the incumbent. The current period of performance ends Oct 26, 2023.

When does Genzyme Corp’s 36C26223F0045 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 26, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Nov 18, 2024 · refreshed monthly